CK 2127107

Drug Profile

CK 2127107

Alternative Names: CK-107; CK-2127107

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Cytokinetics
  • Developer Astellas Pharma; Cytokinetics
  • Class Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Muscular atrophy

Most Recent Events

  • 27 Jul 2016 Cytokinetics and Astellas Pharma agree to co-develop and co-promote CK 2127107 for Amyotrophic lateral sclerosis
  • 30 Jun 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
  • 03 Mar 2016 Cytokinetics has patent protection for CK 2127107 in USA (Cytokinetics, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top